Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | LDHA | P00338 | 2/20 | 0.45 |
| ▸ | LDHB | P07195 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566691 | 1.00 | CES2 (0.59) | CES2CES1LDHALDHBPDE2A | |
| SCHEMBL1566692 | 1.00 | CES2 (0.59) | CES2CES1LDHALDHBPDE2A | |
| SCHEMBL6809648 | 0.84 | ALDH1A1 (0.51) | CES2CES1LDHALDHBPDE2A | |
| SCHEMBL6675458 | 0.83 | CES2 (0.56) | CES2CES1NPSR1EPHX2 | |
| SCHEMBL2484700 | 0.83 | CES2 (0.56) | CES2CES1NPSR1EPHX2 | |
| SCHEMBL5326225 | 0.82 | MAPK1 (0.43) | CES2CES1AKR1C3AKR1C2CFTR | |
| SCHEMBL8084530 | 0.82 | CES2 (0.46) | CES2CES1LDHALDHBPDE2A | |
| SCHEMBL8078579 | 0.82 | HPGD (0.50) | CES2CES1LDHALDHBPDE2A | |
| SCHEMBL4633444 | 0.82 | CES2 (0.59) | CES2CES1EPHX2CNR2 | |
| SCHEMBL952055 | 0.81 | PDE2A (0.46) | CES2CES1LDHALDHBPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| WO-2004037760-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKOXY-1-(TRIFLUOROMETHYL-SUBSTITUTED PHENYL)ETHANOL DERIVATIVES | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | ADH1A, ADH1C, ADH5 | CES2 115/4885CES1 9/4885LDHA 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.